Two reports from the multiple sclerosis get-together in Paris, held last week, caught my attention. The session was a joint meeting of ECTRIMS and ACTRIMS, the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Both items from Paris are of special interest to me, as I have personal experience of them. The … Continue reading New MS studies unveiled at Paris meeting
delay
U-turn over plans to delay treatment for people who are newly-diagnosed with MS
Multiple sclerosis campaigners, led by the MS Society, are celebrating a significant victory. They opposed plans to delay access to disease modifying therapies (DMTs) for people newly diagnosed with MS in Northern Ireland. This is a UK area where certain powers, including responsibility for the National Health Service, are devolved from central government. And, the … Continue reading U-turn over plans to delay treatment for people who are newly-diagnosed with MS
New MS drug approval delayed by three months
People with MS who have been looking forward to the long-awaited US Food and Drug Administration (FDA) approval of the MS drug Ocrevus (ocrelizumab) are disappointed now it has been delayed. This is because, although a decision had been promised for late December 2016, an 11th-hour decision means the approval hearing has now been put … Continue reading New MS drug approval delayed by three months
50shadesofsun 